|

KRT-232 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Kartos Therapeutics, Inc.1

Indications

  • Chronic Myeloid Leukemia1
  • Cancer1

Birmingham, Alabama1 trial

KRT-232 and TKI Study in Chronic Myeloid Leukemia

University of Alabama Birmingham

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.